AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$AXGN

TYNDALL JOSEPH A. sold $174K of AXGN

TYNDALL JOSEPH A. sold 3,500 shares of Axogen, Inc. (AXGN) at $49.70 ($0.17M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · TYNDALL JOSEPH A.
Published Sep 4, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AXGN
Neutral
medium confidence
Mentioned
$AXGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXGNNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, suggesting low informational content for traders.

02

Market read

Limited relevance; likely no immediate price impact.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: filing posted on 2026-09-04, sale dated 2026-09-02

Background

Form 4 filings disclose insider transactions; director sales are monitored for potential signals.

Company-level read

Ticker impact

$AXGNNeutralMedium confidence
Context

Director Joseph Tyndall sold 3,500 shares of Axogen for $173,939.50 on 2026-09-02 via a 10b5‑1 plan.

Expected impact

Minimal short‑term price pressure; likely absorbed without significant move.

Evidence & confidence

The transaction size (~$174k) is low for a director and executed under a pre‑arranged plan, reducing informational value.

Market effects

Sector

None significant for the broader biotech sector.

Regional

No regional effect.

Global

Limited to Axogen shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • Company
    Axogen, Inc.

    US‑listed biotech (NASDAQ: AXGN) developing nerve repair technologies.

  • Individual
    Joseph Tyndall

    Director of Axogen executing a 10b5‑1 sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AXGN insider trading history →

Related articles

OCT 1
$AXGNMed

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Axogen, Inc. (AXGN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair ALACHUA and TAMPA, FL – October 1, 2026 - Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in devel

SEC EDGAR 8-K2 min
SEP 14
$AXGNHighAI 9/10

Axogen to acquire BioCircuit Technologies

Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for $200 million in cash, expected to close in Q4 2026. BioCircuit's NerveTape™ technology, which simplifies nerve repair, complements Axogen's portfolio. The deal is expected to boost revenue growth, adjusted EBITDA margin, and adjusted earnings per share post-closing, while maintaining positive free cash flow, according to Axogen.

medicalbuyer.co.in2 min
SEP 11
$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

rttnews.com3 min
SEP 10
$AXGNHighAI 9/10

Why is Axogen stock sliding today?

Axogen (AXGN) stock fell 9.0% in pre-market trading after announcing a $200M acquisition of BioCircuit Technologies and a $208.7M equity raise at a 10% discount. The deal includes a 30-day over-allotment option. Axogen expects the acquisition to boost revenue, EBITDA, and earnings. The stock drop is attributed to the discounted equity offering.

investing.com2 min